Chemohormonal Therapy: New Paradigm in the Treatment of Metastatic Prostate Cancer—Why, When, and How?
-
00:00
1.
How Low Should Serum Testosterone Level Be in the Treatment of Metastatic Prostate Cancer
-
00:19
2.
Therapy-induced HeterogeneityThe Androgen-receptor (AR) Pathway
-
01:19
3.
Castration-Resistant Prostate Cancer (CRPC): Definition
-
01:56
4.
Testosterone Characteristics
-
02:52
5.
Methods for Serum Testosterone Measurement
-
03:39
6.
Typical Serum Testosterone Values arePresented in Different Units
-
05:50
7.
Management of CRPC: Maintenance of Castrate Testosterone Levels
-
07:30
8.
Testosterone levels during ADT may Serve as anEarly Predictor of Prostate Cancer Progression
-
08:45
9.
Testosterone Levels during ADT may Predict Risk of Disease Progression
-
09:05
10.
Survival Free of AIP According to Serum Testosterone Level
-
09:29
11.
Sustained Profound Suppression of Testosterone May Affect Prognosis and Survival
-
09:53
12.
The Cumulative Side Effects ofAndrogen Deprivation Syndrome
-
10:38
13.
Long-term Side Effects of ADT
-
10:49
14.
Rationale of Intermittent Androgen Deprivation (IAD)
-
11:55
15.
ADT in Advanced Prostate Cancer:Is IAD the New Standard of Care?
-
13:39
16.
Intermittent versus Continuous Androgen Deprivation in Metastatic Hormone Sensitive Prostate Cancer
-
14:53
17.
Slide 17
-
15:31
18.
Low Nadir Serum Testosterone (<20 ng/dL) within the first year of ADT Predicts Treatment Outcomes
-
16:18
19.
Clinical Implication for Patients on Androgen Deprivation Therapy
-
17:43
20.
Bipolar Androgen Therapy (BAT): Adaptive auto-regulation of AR and induction of DNA damage with testosterone therapy
-
19:34
21.
Slide 21
-
21:46
22.
Thank You for Your Attentions
- 索引
- 筆記
- 討論
- 全螢幕
How Low Should Plasma Testosterone Level Be in the Treatment of Metastatic Prostate Cancer? ‐New Inspiration from Next Generation Hormonal Agents
長度: 24:06, 瀏覽: 971, 最近修訂: 2017-05-19
-
00:00
1.
How Low Should Serum Testosterone Level Be in the Treatment of Metastatic Prostate Cancer
-
00:19
2.
Therapy-induced HeterogeneityThe Androgen-receptor (AR) Pathway
-
01:19
3.
Castration-Resistant Prostate Cancer (CRPC): Definition
-
01:56
4.
Testosterone Characteristics
-
02:52
5.
Methods for Serum Testosterone Measurement
-
03:39
6.
Typical Serum Testosterone Values arePresented in Different Units
-
05:50
7.
Management of CRPC: Maintenance of Castrate Testosterone Levels
-
07:30
8.
Testosterone levels during ADT may Serve as anEarly Predictor of Prostate Cancer Progression
-
08:45
9.
Testosterone Levels during ADT may Predict Risk of Disease Progression
-
09:05
10.
Survival Free of AIP According to Serum Testosterone Level
-
09:29
11.
Sustained Profound Suppression of Testosterone May Affect Prognosis and Survival
-
09:53
12.
The Cumulative Side Effects ofAndrogen Deprivation Syndrome
-
10:38
13.
Long-term Side Effects of ADT
-
10:49
14.
Rationale of Intermittent Androgen Deprivation (IAD)
-
11:55
15.
ADT in Advanced Prostate Cancer:Is IAD the New Standard of Care?
-
13:39
16.
Intermittent versus Continuous Androgen Deprivation in Metastatic Hormone Sensitive Prostate Cancer
-
14:53
17.
Slide 17
-
15:31
18.
Low Nadir Serum Testosterone (<20 ng/dL) within the first year of ADT Predicts Treatment Outcomes
-
16:18
19.
Clinical Implication for Patients on Androgen Deprivation Therapy
-
17:43
20.
Bipolar Androgen Therapy (BAT): Adaptive auto-regulation of AR and induction of DNA damage with testosterone therapy
-
19:34
21.
Slide 21
-
21:46
22.
Thank You for Your Attentions
- 位置
-
- 資料夾名稱
- 2015臺大攝護祭-醫藥護人員場
- 發表人
- 系統管理者
- 單位
- 泌尿部
- 建立
- 2017-05-19 17:00:04
- 最近修訂
- 2017-05-19 19:10:42
- 長度
- 24:06